ReviewCurrent oncology reports2026
Advances in Radiotherapy for Soft Tissue Sarcomas in 2025: A Review.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review aims to synthesize and critically appraise the most impactful advances in radiotherapy (RT) for soft tissue sarcomas (STSs) reported in 2025, with a focus on technological innovations, fractionation paradigms, combination strategies, and personalized approaches. RECENT
findingsThe year 2025 has witnessed the increasing acceptance of hypofractionated RT as an effective alternative in multiple settings, offering non-inferior efficacy with improved convenience. Prospective and real-world evidence consistently validates preoperative moderately hypofractionated radiotherapy for extremity/superficial trunk STS, with mature local control and acceptable toxicity. Stereotactic body radiotherapy and particle therapy have expanded their roles, particularly in recurrent, metastatic, or pediatric STS. Robust evidence supports synergistic combinations of RT with targeted agents (e.g., PARP inhibitors, pazopanib) and immunotherapy, especially in high-risk subtypes. Advances in multiparametric MRI and pathological biomarkers (e.g., hyalinization, tumor-infiltrating monocytes) enable early response assessment and prognostication, paving the way for adaptive, personalized RT. Radiotherapy for STSs in 2025 is characterized by personalized, precision-based approaches that improve local control, reduce toxicity, and preserve quality of life. Continued integration of advanced technologies, biomarker-guided strategies, and novel systemic combinations will further optimize outcomes. Future efforts should focus on validating surrogate endpoints, enhancing global access, and incorporating artificial intelligence into adaptive workflows. Careful attention to RT-related toxicities is critical for balancing efficacy and safety in practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.